References
- Natural history and clinical management of central retinal vein occlusionThe Central Vein Occlusion Study GroupArch Ophthalmol19971154864919109757
- MitchellPSmithWChangAPrevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye StudyArch Ophthalmol1996114124312478859084
- KleinRKleinBEMossSEMeuerSMThe epidemiology of retinal vein occlusion: the Beaver Dam Eye StudyTrans Am Ophthalmol Soc20009813314111190017
- RogersSMcIntoshRLCheungNInternational Eye Disease ConsortiumThe prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and AustraliaOphthalmology201011731331920022117
- McIntoshRLRogersSLLimLNatural history of central retinal vein occlusion: an evidence-based systematic reviewOphthalmology20101171113112320430446
- AielloLPAveryRLArriggPGVascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disordersN Engl J Med1994331148014877526212
- ParkSPAhnJKMunGHAqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusionRetina (Philadelphia, PA)201030281286
- NomaHFunatsuHMimuraTEguchiSShimadaKRole of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusionBr J Ophthalmol20119578879221109696
- BrownDMCampochiaroPASinghRPCRUISE InvestigatorsRanibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III studyOphthalmology20101171124.e1e1133.e120381871
- HolzFGRoiderJOguraYVEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO studyBr J Ophthalmol20139727828423298885
- BoyerDHeierJBrownDMVascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS studyOphthalmology20121191024103222440275
- EpsteinDLAlgverePVvon WendtGSeregardSKvantaABenefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized studyOphthalmology20121192587259122902212
- EpsteinDLAlgverePVvon WendtGSeregardSKvantaABevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical studyOphthalmology20121191184118922424833
- PretiRCRamirezLMPimentelSLEffect of a single intravitreal bevacizumab injection on contrast sensitivity and macular thickness in eyes with macular edema from central retinal vein occlusion: a prospective, nonrandomized, three-month follow-up studyOphthalmic Res20145114014524525617
- PikkelJChassidOBusoolYSrourWSharabi-NovABeiranIBevacizumab for CRVO associated CME: effect of timing and frequency of injections on final visual outcomeJ Ophthalmol2013201397467024490054
- Axer-SiegelRDotanAMimouniKBorEWeinbergerDBourlaDHIntravitreous bevacizumab treatment for macular edema due to central retinal vein occlusionCurr Eye Res20123781882222668313
- DeCroosFCEhlersJPStinnettSFekratSIntravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs ischemic and early vs late treatmentCurr Eye Res2011361164117021978179
- IturraldeDSpaideRFMeyerleCBIntravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term studyRetina20062627928416508427
- MartinDFMaguireMGYingGSRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med20113641897190821526923
- AhnSJAhnJWooSJParkKHInitial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusionBiomed Res Int2013201320973524066287